Published in Eur Urol on October 01, 2004
Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res (2007) 1.62
Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J (2008) 1.42
Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev (2009) 1.37
Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci (2008) 1.24
Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer (2010) 1.18
Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids Surf B Biointerfaces (2011) 1.14
Hyalurondiase: both a tumor promoter and suppressor. Semin Cancer Biol (2008) 1.02
Molecular screening for bladder cancer: progress and potential. Nat Rev Urol (2010) 0.97
Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther (2013) 0.96
Immunohistochemical detection of hTERT in urothelial lesions: a potential adjunct to urine cytology. Cytojournal (2006) 0.96
Clinical states model for biomarkers in bladder cancer. Future Oncol (2009) 0.92
Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res (2010) 0.92
The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Ther Adv Urol (2011) 0.92
Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer. Rev Urol (2006) 0.84
Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis. Curr Med Chem (2012) 0.83
Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? Expert Rev Anticancer Ther (2008) 0.83
Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Rev Proteomics (2009) 0.82
Which urine marker test provides more diagnostic value in conjunction with standard cytology- ImmunoCyt/uCyt+ or Cytokeratin 20 expression. Diagn Pathol (2009) 0.80
ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: A meta-analysis. Oncol Lett (2016) 0.78
Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise. Indian J Urol (2015) 0.75
[Urinary cytology. Possibilities, limitations and the future]. Urologe A (2006) 0.75
Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol (2008) 4.25
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol (2007) 2.50
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2007) 2.41
Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence. J Urol (2009) 2.36
Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol (2008) 2.32
Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur Urol (2008) 2.31
Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy. Eur Urol (2006) 2.21
Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol (2007) 2.16
Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res (2007) 2.12
Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. Eur Urol (2008) 2.02
Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol (2005) 1.97
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
Development and external validation of an extended 10-core biopsy nomogram. Eur Urol (2006) 1.90
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol (2008) 1.86
Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol (2009) 1.83
Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer (2003) 1.82
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Prediction of postoperative sexual function after nerve sparing radical retropubic prostatectomy. J Urol (2006) 1.77
Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol (2008) 1.74
Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol (2006) 1.73
HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol (2009) 1.72
Prostate cancer nomograms: an update. Eur Urol (2006) 1.71
A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol (2004) 1.71
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Incremental detection rate of prostate cancer by real-time elastography targeted biopsies in combination with a conventional 10-core biopsy in 1024 consecutive patients. BJU Int (2014) 1.66
Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol (2007) 1.65
Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. Eur Urol (2007) 1.62
Molecular cancer phenotype in normal prostate tissue. Eur Urol (2008) 1.58
Major postoperative complications secondary to use of the Bookwalter self-retaining retractor. Urology (2002) 1.55
The feasibility of prostate cancer detection by triple spectroscopy. Eur Urol (2008) 1.55
Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies. Eur Urol (2010) 1.54
Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol (2008) 1.51
Tumor volume in insignificant prostate cancer: increasing threshold gains increasing risk. Prostate (2014) 1.50
Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer (2008) 1.48
Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res (2008) 1.48
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology (2005) 1.48
Functional and oncological outcomes of patients aged <50 years treated with radical prostatectomy for localised prostate cancer in a European population. BJU Int (2013) 1.47
Prostate cancers in the transition zone: Part 2; clinical aspects. BJU Int (2004) 1.46
Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma. Eur Urol (2012) 1.46
Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol (2005) 1.45
Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. Eur Urol (2007) 1.45
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol (2007) 1.45
Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. Eur Urol (2008) 1.45
Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. Eur Urol (2003) 1.44
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol (2006) 1.42
CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res (2013) 1.42
Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer (2008) 1.39
The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. Eur Urol (2006) 1.38
High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol (2006) 1.38
Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int (2010) 1.37
Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res (2007) 1.36
Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer (2004) 1.34
Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res (2009) 1.31
High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate (2010) 1.28
Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res (2010) 1.28
Effect of body mass index on histopathologic parameters: results of large European contemporary consecutive open radical prostatectomy series. Urology (2008) 1.27
Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci (2008) 1.24
Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. Eur Urol (2003) 1.24
Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res (2003) 1.22
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol (2013) 1.22
Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int (2010) 1.22
Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics (2005) 1.20
Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer (2007) 1.19
Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer (2010) 1.18
Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer (2005) 1.18
Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer (2006) 1.17
Open retropubic nerve-sparing radical prostatectomy. Eur Urol (2005) 1.16
Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol (2012) 1.16
Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res (2011) 1.15
Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. BJU Int (2006) 1.15
Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res (2008) 1.13
Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int (2006) 1.12
Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int (2014) 1.12
Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol (2002) 1.12
Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int (2008) 1.11
Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol (2004) 1.11
CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. Transplantation (2004) 1.11
Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol (2010) 1.09
Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer (2007) 1.09
Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical failure. Eur Urol (2005) 1.09
Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer (2007) 1.09
Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol (2007) 1.08